• Explore /
  • Poster
  • / Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.

Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.

Abstract Video & Slides Poster

Authors

Thomas Martin

Thomas G. Martin

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Thomas G. Martin , Philippe Moreau , Saad Zafar Usmani , Alfred L. Garfall , Maria-Victoria Mateos , Jesús F. San-Miguel , Albert Oriol Rocafiguera , Ajay K. Nooka , Laura Rosiñol , Ajai Chari , Lionel Karlin , Amrita Y. Krishnan , Nizar J. Bahlis , Rakesh Popat , Britta Besemer , Joaquin Martinez , Michel Delforge , John Fastenau , Katharine S. Gries , Niels W.C.J. van de Donk

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04557098

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8033)

DOI

10.1200/JCO.2022.40.16_suppl.8033

Abstract #

8033

Poster Bd #

457

Abstract Disclosures

Similar Posters

First Author: Robert M. Rifkin

First Author: Michel Delforge

First Author: Paula Rodríguez-Otero

First Author: Niels W.C.J. van de Donk